150 related articles for article (PubMed ID: 37595359)
1. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Freeman SD; Thomas A; Thomas I; Hills RK; Vyas P; Gilkes A; Metzner M; Jakobsen NA; Kennedy A; Moore R; Almuina NM; Burns S; King S; Andrew G; Gallagher KME; Sellar RS; Cahalin P; Weber D; Dennis M; Mehta P; Knapper S; Russell NH
Blood; 2023 Nov; 142(20):1697-1707. PubMed ID: 37595359
[TBL] [Abstract][Full Text] [Related]
2. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
4. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Jaramillo S; Krisam J; Le Cornet L; Kratzmann M; Baumann L; Sauer T; Crysandt M; Rank A; Behringer D; Teichmann L; Görner M; Trappe RU; Röllig C; Krause S; Hanoun M; Hopfer O; Held G; Buske S; Fransecky L; Kayser S; Schliemann C; Schaefer-Eckart K; Al-Fareh Y; Schubert J; Geer T; Kaufmann M; Brecht A; Niemann D; Kieser M; Bornhäuser M; Platzbecker U; Serve H; Baldus CD; Müller-Tidow C; Schlenk RF
Trials; 2021 Nov; 22(1):765. PubMed ID: 34732236
[TBL] [Abstract][Full Text] [Related]
6. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
[TBL] [Abstract][Full Text] [Related]
7. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
[TBL] [Abstract][Full Text] [Related]
8. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
9. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE
Cancer; 2013 Nov; 119(22):4036-43. PubMed ID: 24006085
[TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
[TBL] [Abstract][Full Text] [Related]
11. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
Bourne G; Diebold K; Espinoza-Gutarra M; Al-Kadhimi Z; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R; Jamy O
Leuk Res; 2024 Apr; 139():107467. PubMed ID: 38460432
[TBL] [Abstract][Full Text] [Related]
12. Gemtuzumab ozogamicin for
Lambert J; Pautas C; Terré C; Raffoux E; Turlure P; Caillot D; Legrand O; Thomas X; Gardin C; Gogat-Marchant K; Rubin SD; Benner RJ; Bousset P; Preudhomme C; Chevret S; Dombret H; Castaigne S
Haematologica; 2019 Jan; 104(1):113-119. PubMed ID: 30076173
[TBL] [Abstract][Full Text] [Related]
13. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
Burnett AK; Hills RK; Milligan D; Kjeldsen L; Kell J; Russell NH; Yin JA; Hunter A; Goldstone AH; Wheatley K
J Clin Oncol; 2011 Feb; 29(4):369-77. PubMed ID: 21172891
[TBL] [Abstract][Full Text] [Related]
14. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Petersdorf SH; Kopecky KJ; Slovak M; Willman C; Nevill T; Brandwein J; Larson RA; Erba HP; Stiff PJ; Stuart RK; Walter RB; Tallman MS; Stenke L; Appelbaum FR
Blood; 2013 Jun; 121(24):4854-60. PubMed ID: 23591789
[TBL] [Abstract][Full Text] [Related]
15. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
16. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
17. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
Derman BA; Larson RA
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101102. PubMed ID: 31779969
[TBL] [Abstract][Full Text] [Related]
18. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
Burnett A; Cavenagh J; Russell N; Hills R; Kell J; Jones G; Nielsen OJ; Khwaja A; Thomas I; Clark R;
Haematologica; 2016 Jun; 101(6):724-31. PubMed ID: 26921360
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
[TBL] [Abstract][Full Text] [Related]
20. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Amadori S; Suciu S; Stasi R; Salih HR; Selleslag D; Muus P; De Fabritiis P; Venditti A; Ho AD; Lübbert M; Thomas X; Latagliata R; Halkes CJ; Falzetti F; Magro D; Guimaraes JE; Berneman Z; Specchia G; Karrasch M; Fazi P; Vignetti M; Willemze R; de Witte T; Marie JP
J Clin Oncol; 2013 Dec; 31(35):4424-30. PubMed ID: 24127442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
